Skip to main content

TNF inhibitor

Different Regimens but Equal Outcomes in Polyarticular JIA

Sep 15, 2021

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.



This prospective observational study used data from the STOP-JIA trial (Start Time Optimization of

Read Article

High Drug Switching and Low Persistence in Rheumatoid Arthritis

Sep 13, 2021

Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.



This retrospective analysis assessed treatment patterns among patients newly initiated on biologic

Read Article
ICYMI: The Greatest Rheumatologist - Part I Who is the greatest rheumatologist? What makes for a great rheum? Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring? #RheumNow https://t.co/aNKnYtlN4I https://t.co/FBNXuKnbiA
Dr. John Cush @RheumNow( View Tweet )
Sep 07, 2021
ICYMI Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors https://t.co/omeZyprT96 https://t.co/UGBlb9m5bS
Dr. John Cush @RheumNow( View Tweet )
Sep 05, 2021

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Sep 02, 2021

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

Read Article

TNF Inhibitor Induced IgA Vasculitis in IBD

Aug 31, 2021

A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after  or during anti-TNF-α therapy.



A retrospectively analysis of the GETAID and FVSG networks identified, 43 patients

Read Article
Tumor necrosis factor inhibitors (TNFi) are frequently used first line in rheumatoid arthritis (RA) patients; and a new analysis shows that repeat use of TNFi dominates over the use of non-TNFi biologics when the initial TNFi therapy has failed. https://t.co/hmFZKrMdJ1 https://t.co/whCPvAAMMi
Dr. John Cush @RheumNow( View Tweet )
Aug 31, 2021
Large US Behcets disease registry in USA: 1023 pts w/ more women (79%) than expected. Most frequently Meds: steroids (68%), colchicine-COL (55%), MTX (22%), TNFi (29%); only 3.2% apremilast. Less COL, CsA, CTX vs use in Egypt/Turkey/Iran https://t.co/hpHO6C8LKW

Dr. John Cush @RheumNow( View Tweet )

Aug 31, 2021

Drug Choices After First TNF Inhibitor in RA

Aug 30, 2021

TNFi are frequently used first line in RA patients; and a new analysis shows that repeat use of TNFi dominates over the use of non-TNFi biologics when the initial TNFi therapy has failed. This retrospective analysis of commercial insurance records analyzed the patterns of drug use in adult RA

Read Article

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

Aug 26, 2021

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Read Article

ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs

ACR Press Release
Aug 25, 2021

The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an available mRNA

Read Article

Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis

Aug 24, 2021

Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA).



Analysis of electronic medical records of a large HMO identfied psoriasis patients who had received treatment for psoriasis (but were

Read Article
Rheums--have a question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wzNmOzH4VE https://t.co/QJn6Uo3lbM
Dr. John Cush @RheumNow( View Tweet )
Aug 24, 2021

EULAR Points on Managing Difficult Rheumatoid Arthritis

Aug 19, 2021

A EULAR task force has promulgated several points to consider in managing difficult-to-treat RA. These "points" are unique in directing the rheumatologist's attention to the potential for misdiagnosis and the impact of comorbid conditions on what is perceived as poorly controlled RA.

Read Article
New study data on mRNA vaccines in pts with inflammatory diseases on mostly #TNFi +/- #csDMARDs . ▶️ Effective immune response (lower than healthy controls) ▶️Comparable side effects ▶️ no ⬆️ in DAS28 ▶️ no pts on #Rituximab included https://t.co/aexdFoUzer https://t.co/h1S1S2YsHS
ARD & RMD Open @ARD_BMJ( View Tweet )
Aug 13, 2021

Biologics Reduce Surgical Needs in RA

Aug 10, 2021

In Canada, biologic DMARDs (bDMARDs) were introduced after 2001, and since that time there have been significant reductions in hip and knee arthroplasty (THA/TKA) among patients with rheumatoid arthritis (RA), but not in patients with osteoarthritis (OA).



A cohort of RA and OA

Read Article

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Aug 06, 2021

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article

Rheumatoid Arthritis Offspring Show Normal School Performance

Aug 02, 2021

A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.



This study included Danish children born 1995–2008 (n=934) and compared to non-RA

Read Article

Shingles Risk with JAK Inhibitors and Other Biologics

Jul 29, 2021

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.



RA patients from the German RABBIT register were prospectively enrolled (2007 - 2020)

Read Article

No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis

Jul 29, 2021

The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).

Read Article

Cardiovascular Prevention Lacking in Rheumatoid Arthritis

Jul 28, 2021

An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).

Read Article

DMARD Effects on COVID-19 Outcomes

Jul 26, 2021

Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (

Read Article

Tofacitinib Efficacy in Ankylosing Spondylitis

Jul 22, 2021

Deodhar and colleagues have published the results of a study showing that in adult patients with active ankylosing spondylitis (AS), oral tofacitinib was effective (versus placebo) and is safe. 

Read Article
Metanalysis of 39 studies, 15,673 pts with nail psoriasis = 100% improvement of the Nail Psoriasis Severity Index, ixekizumab was best @ 24 wks (OR 2.98; 95% CI, 1.74-5.10), followed by TNF inhibitor (infliximab, adalimumab). https://t.co/VnhbMPYEV7

Dr. John Cush @RheumNow( View Tweet )

Jul 21, 2021
Study of 33 RCTs, 4544 pts Rx w/ either IL-17 or TNF inhibitors finds lower risk of UVEITIS with anti-TNF mAb (vs PBO OR = 0.46; vs IL-17i OR = 0.34. IL-17 inhibitors are not protective against uveitis https://t.co/AIxgI2qhq9

Dr. John Cush @RheumNow( View Tweet )

Jul 19, 2021
×